DWP16001 Placebo

DRUG3 trials

Sponsors

Daewoong Pharmaceutical Co. LTD.

Conditions

Diabetes MellitusDiabetes Mellitus, Type 2Endocrine System DiseasesGlucose Metabolism DisordersMetabolic DiseaseType 2 Diabetes MellitusType 2 Diabetic Nephropathy

Phase 3

A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes Mellitus

RecruitingNCT05466643

Daewoong Pharmaceutical Co. LTD.Type 2 Diabetes Mellitus

Start: 2023-03-17End: 2024-09-30Target: 240Updated: 2024-04-08

The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin

Active, not recruitingNCT05505994

Daewoong Pharmaceutical Co. LTD.Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases +2

Start: 2022-09-28End: 2024-09-30Updated: 2024-04-04

Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients

Not yet recruitingNCT06606093

Daewoong Pharmaceutical Co. LTD.Type 2 Diabetic Nephropathy

Start: 2024-09-23End: 2027-01-31Target: 348Updated: 2024-09-20

Related Papers

Efficacy and Safety of Enavogliflozin as Add-on in Adults with Type 2 Diabetes Mellitus Inadequately Controlled with Insulin or Insulin with Other Antidiabetic Drugs.

2025-12-15